A detailed history of Geode Capital Management, LLC transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 864,528 shares of ABOS stock, worth $2.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
864,528
Previous 812,133 6.45%
Holding current value
$2.07 Million
Previous $1.97 Million 9.11%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.22 - $3.54 $116,316 - $185,478
52,395 Added 6.45%
864,528 $2.14 Million
Q2 2024

Aug 09, 2024

BUY
$2.14 - $4.01 $1.13 Million - $2.11 Million
526,994 Added 184.82%
812,133 $1.97 Million
Q1 2024

May 13, 2024

BUY
$2.97 - $4.64 $60,991 - $95,287
20,536 Added 7.76%
285,139 $1.15 Million
Q3 2023

Nov 13, 2023

BUY
$4.15 - $9.72 $405,799 - $950,450
97,783 Added 58.62%
264,603 $1.1 Million
Q4 2022

Feb 13, 2023

BUY
$4.81 - $10.17 $44,131 - $93,309
9,175 Added 5.82%
166,820 $900,000
Q3 2022

Nov 14, 2022

BUY
$4.44 - $10.48 $216,654 - $511,382
48,796 Added 44.83%
157,645 $1.58 Million
Q2 2022

Aug 12, 2022

SELL
$3.08 - $4.88 $720,094 - $1.14 Million
-233,797 Reduced 68.23%
108,849 $511,000
Q1 2022

May 13, 2022

BUY
$3.91 - $6.73 $667,698 - $1.15 Million
170,767 Added 99.35%
342,646 $1.34 Million
Q4 2021

Feb 11, 2022

BUY
$6.54 - $15.31 $419,037 - $980,957
64,073 Added 59.43%
171,879 $1.16 Million
Q3 2021

Nov 12, 2021

BUY
$14.5 - $20.28 $1.56 Million - $2.19 Million
107,806 New
107,806 $1.6 Million

Others Institutions Holding ABOS

About Acumen Pharmaceuticals, Inc.


  • Ticker ABOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,503,100
  • Market Cap $97.2M
  • Description
  • Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...
More about ABOS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.